Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution.
about
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsMyelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Risk assessment in chronic myelomonocytic leukemia (CMML).A case-control study of chronic myelomonocytic leukemia (CMML) in Shanghai, China: evaluation of risk factors for CMML, with special focus on benzene.Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes.Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
P2860
Q33377270-82F59524-7DAD-4106-A7F8-3BE6031731C6Q35848032-21221A43-E101-4B47-8638-125DAAABCBB1Q36876853-6F318A37-73E2-41DE-9FBB-234F2D8E8AFBQ38012085-A3729F56-0F04-4BA8-B4E8-22F2C3239BB3Q38130476-2CAD7680-9FB7-4692-8267-C49DABD899D5Q38134374-AF896E19-72D5-4847-A3B2-3F3E70D17F5EQ38644826-8D3DFF19-0AF4-45DB-B843-414ACB6DFF18Q38835771-DD88A046-13F8-44E1-ADCF-73947D066759Q43529062-191F1906-EBD7-4C40-83FB-39BB20AAAB89Q44221702-EB5649DE-3EA0-4B13-B6B9-836F74612DBBQ47094379-6F9903DE-038C-480F-B296-6D991433EFA1Q47853133-AB980965-C415-4F8F-9EFB-D392CEA56552Q53066596-FC471152-C7F5-402E-8C41-3E31615ADBD7Q57219633-E037D6BE-F252-4BB7-A250-2636AA1BE168
P2860
Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Dysplastic versus proliferativ ...... nts from a single institution.
@ast
Dysplastic versus proliferativ ...... nts from a single institution.
@en
Dysplastic versus proliferativ ...... nts from a single institution.
@nl
type
label
Dysplastic versus proliferativ ...... nts from a single institution.
@ast
Dysplastic versus proliferativ ...... nts from a single institution.
@en
Dysplastic versus proliferativ ...... nts from a single institution.
@nl
prefLabel
Dysplastic versus proliferativ ...... nts from a single institution.
@ast
Dysplastic versus proliferativ ...... nts from a single institution.
@en
Dysplastic versus proliferativ ...... nts from a single institution.
@nl
P2093
P1433
P1476
Dysplastic versus proliferativ ...... nts from a single institution.
@en
P2093
Nösslinger T
Pfeilstöcker M
Pittermann E
P304
P356
10.1016/S0145-2126(01)00014-5
P577
2001-09-01T00:00:00Z